Rank ligand as a target in musculoskeletal neoplasms.

Abstract

Receptor activator of nuclear factor-κB ligand (RANKL) is a tumor necrosis factor (TNF) family member, which signals through the osteoclast surface RANK. As such, RANKL is required for osteoclast differentiation and function, namely bone resorption. There is now growing evidence that RANKL is a therapeutic target for musculoskeletal neoplasms, namely giant cell tumor of bone (GCTB) and osteosarcoma.

• Authors: Gregory M Cote
• Journal: Current reviews in musculoskeletal medicine (Curr Rev Musculoskelet Med) Vol. 8 Issue 4 Pg. 339-43 (Dec 2015) ISSN: 1935-973X [Print] United States
• PMID: 26452557 (Publication Type: Journal Article)